🚨 Potential breakthrough in pancreatic cancer at #ASCO2026.
The Phase III RASolute-302 trial showed that the pan-RAS inhibitor daraxonrasib (RMC-6236) nearly doubled median overall survival in previously treated metastatic pancreatic cancer.
https://t.co/ZXe2zdWQr4
Excited to share that my PhD research is now published in the Journal of Biomedical and Toxicology!
“Pindolol Mitigates Cancer Cachexia by Modulating Inflammation, Lipolysis, and Muscle Atrophy”
https://t.co/I09ScVyoeT
New research article
Sex-specific survival but not tissue wasting in the KPP mouse model of pancreatic cancer-induced cachexia
@ErinETalbert
https://t.co/8bE6JE2cv4
New Research Article
Pancreatic Cancer Induces Population-Specific Switching of Myosin Isoforms and Discrete Activation of Cachexia Genes in Skeletal Muscle Myocytes.
@BrittCounts
https://t.co/MGqOjAhVCo
📢 We have launched a new symbol for Cancer Cachexia!! 📢 Our call to unite, act, and raise awareness. Join our movement. #CCAD2025#CachexiaWastingMatters 💙🧡🩵 Help us spread the word! September 26th, 2025 - First-ever Cancer Cachexia Awareness Day!!